title: [Myeloablative chemo- and radiotherapy with autologous and allogenic bone marrow reconstitution in children with metastatic neuroblastoma].
abstract: 22 children with metastatic neuroblastoma received myeloablative chemoradiotherapy followed by bone marrow transplantation (BMT). The duration of preceding chemotherapy was 4-30 months and included treatment of recurrences in 10 children. At BMT 12 patients were in CR, 9 in PR and one had tumor progression. 10/15 of autologous bone marrows were purged using immunomagnetic bead method of Kemshead and 2/15 using 4 hydroperoxycyclophosphamide. Myeloablative therapy consisted of melphalan and total body irradiation (TBI) in 13 patients (three each supplemented by vincristine or adriamycin/etoposide), in one child of melphalan and mIBG and in 3 children of melphalan alone. 3 children received double autograft and 2 cyclophosphamide (and TBI). 10 patients survived 0-32 months from BMT and 5-48 months from diagnosis, respectively. 12 patients died including 7/12 of tumor progression and 5/12 of toxicity (venoocclusive disease, gut toxicity, septicemia, pneumonia). We conclude that at this point BMT after conventional high dose chemotherapy may provide the only real chance of survival for a significant number of children with metastatic neuroblastoma.
authors.affiliation: Universitäts-kinderkliniken Köln.
authors.forename: F
authors.initials: F
authors.lastname: Berthold
authors.forename: C
authors.initials: C
authors.lastname: Bender-Götze
authors.forename: R
authors.initials: R
authors.lastname: Dopfer
authors.forename: R
authors.initials: R
authors.lastname: Erttmann
authors.forename: R J
authors.initials: RJ
authors.lastname: Haas
authors.forename: G
authors.initials: G
authors.lastname: Henze
authors.forename: M
authors.initials: M
authors.lastname: Körbling
authors.forename: H
authors.initials: H
authors.lastname: Riehm
authors.forename: M
authors.initials: M
authors.lastname: Rister
authors.forename: B
authors.initials: B
authors.lastname: Stollmann
mesh_terms: D000008:Abdominal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D000310:Adrenal Gland Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects / Q000528:radiation effects; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D009362:Neoplasm Metastasis; D009447:Neuroblastoma / Q000188:drug therapy* / Q000532:radiotherapy; D013899:Thoracic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy
vernacular_title: Myeloablative Chemo- und Radiotherapie mit autologer und allogener Knochenmarksrekonstitution bei Kindern mit metastasiertem Neuroblastom.